US REGULATORY RECORDS
- FDA API DMF records
- 4
- Active (A)
- 4
- Inactive (I)
- 0
FDA list cutoff:
ACTIVE PHARMACEUTICAL INGREDIENT
Research Abrocitinib API through FDA DMF and China CDE records. Compare reported companies, interpret registration status and check chemical identity before preparing a sourcing or dossier review.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
This Abrocitinib profile uses the free-base reference identity, CAS 1622902-68-4. Records are selected by reported substance name; neither source supplies a CAS field to verify the chemical form of every filing. Registry inclusion does not establish supplier qualification or current availability.
Abrocitinib registry coverage: FDA API DMF entries (4) and CDE API registrations (1), selected by substance name. Browse free samples, then subscribe to search, filter and export the complete available records.
FDA list cutoff:
CDE export captured:
0 documented company-name correspondences
The registries have different snapshot dates and status definitions. Counts describe records, not qualified suppliers. Company fields retain their original wording. No cross-registry company-name correspondences are documented for this profile.
$19.00 per month
$149.00 per year
Billed $149.00 every year
Abrocitinib coverage: FDA DMF records (4) and CDE registrations (1). Free CSV samples contain the preview rows; a subscription opens the complete available records.
One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.
Use the Abrocitinib registry tables below to inspect original holder and company fields. No cross-registry company-name correspondences are documented. Similar names, translations or membership of the same group do not verify an identical legal entity or manufacturing site.
Free previewShowing 0 sample records of 0.
0 company-name correspondences
No exact company-name correspondences are documented for these snapshots.
Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.
Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.
US REGULATORY RECORDS
Inspect Abrocitinib DMF holders, reported subjects, initial submission dates and activity codes. Compare the original fields before requesting dossier access. An active filing does not establish a qualified manufacturing site or an available batch.
4Active (A)
0Inactive (I)
A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.
Free previewShowing 3 sample records of 4.
Free preview
More records available with a subscription: 1.
CHINA REGULATORY RECORDS
Inspect Abrocitinib registration numbers, original Chinese company names, packaging and review status. Expand a record to read all eleven source columns, including the reported validity date and fields left blank by the source.
1Approved or qualifying prior approval (A)
0Technical review not passed or unlinked (I)
CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.
Free previewShowing 1 sample records of 1.
Abrocitinib, also known as PF-04965842, is identified here by free-base CAS 1622902-68-4 and UNII 73SM5SF3OR. The FDA-hosted CIBINQO label describes the free base as the active ingredient in the finished tablets. Abrocitinib API is the drug substance, while CIBINQO is a formulated medicine. The reference identity defines this profile; a registry name alone does not establish the composition, solid-state form or specification of an individual material.
Free-base reference identity; the CAS of each individual filing has not been independently verified.
The Abrocitinib formula and molecular weight below describe the free-base reference molecule. For a material comparison, request the stated chemical form, assay basis, impurity specification and batch documentation from the relevant manufacturer. Packaging recorded in a registry describes reported pack sizes; it does not establish minimum order quantities or available stock.
Use these official references to check Abrocitinib identifiers, distinguish the API from finished tablets and interpret the two registries.
Check the reference CAS, UNII, formula and PF-04965842 synonym.
Read the Abrocitinib free-base description and molecular properties in section 11.
Check how a dossier is referenced and why an active listing does not establish approval.
Read the regulator explanation of A and I before comparing Chinese registrations.
This Abrocitinib profile uses free-base CAS 1622902-68-4, formula C14H21N5O2S, molecular weight 323.42 g/mol and UNII 73SM5SF3OR. These are reference identifiers for the page. The FDA and CDE records are selected by substance name and do not individually supply CAS confirmation.
PF-04965842 is a reported synonym for Abrocitinib in the FDA substance record. CIBINQO is a finished-tablet medicine containing the free-base active ingredient together with excipients. A request for bulk API should specify the substance, chemical form and intended specification rather than treating the finished medicine as a raw-material product.
The supplied Q2 2026 workbook yields 4 Type II records with subjects matching ABROCITINIB after trimming whitespace for selection. Original subject text remains intact. Type II also covers intermediates and drug products, so category alone is insufficient to identify an API filing. These entries reflect the workbook cutoff rather than a live search.
No. FDA A means active and I means inactive. FDA states that DMFs are neither approved nor disapproved. An Abrocitinib listing does not establish supplier qualification, manufacturing-site approval, permission to reference the dossier or current availability. Verify the official record and obtain the documentation relevant to your application.
Number of registrations named exactly 阿布昔替尼 in the supplied export: 1. Abrocitinib records retain all eleven source fields, including the reported enterprise name, packaging, validity date and blank specification. The export provides no CAS field. A packaging size is a reported registry value, not an offer, minimum order or stock confirmation.
For Abrocitinib registrations, CDE codes describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I covers technical review not passed or a registration not yet linked to a formulation. Check the current official record before relying on a snapshot status or validity date.
Use the Abrocitinib records to identify reported parties and dossier references, then verify the legal entity, manufacturing site, exact chemical form, specification and right to reference the relevant dossier with the company. Request supporting batch and analytical documents for your intended use. Registry inclusion alone does not establish those points or permission to supply a destination market.
The free Abrocitinib preview shows a limited sample from each registry and provides matching CSV samples. The CDE selection fits entirely within that preview. Overview counts describe the complete selected dataset. A subscription opens the remaining available records, search, status filtering and complete CSV exports. It does not provide quotations, supplier qualification or live registry monitoring.
Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.
U.S. Food and Drug Administration
Links Abrocitinib to CAS 1622902-68-4, UNII 73SM5SF3OR, molecular formula and the PF-04965842 synonym. A UNII identifies a substance and does not establish regulatory approval.
“1622902-68-4”
U.S. Food and Drug Administration
Synonyms and Mappings in the FDA UNII Search Service record for ABROCITINIB.
U.S. Food and Drug Administration; prescribing information for Pfizer CIBINQO
Section 11 identifies the free-base active ingredient and reports its formula and molecular weight. The finished-product label does not qualify the companies listed in this profile.
“tablets contain the free base of abrocitinib”
U.S. Food and Drug Administration; prescribing information for Pfizer CIBINQO
CIBINQO prescribing information, revised June 2026, section 11, printed pages 16–17.
U.S. Food and Drug Administration
The selected filings come from the supplied second-quarter workbook, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.
“ABROCITINIB”
U.S. Food and Drug Administration
Reported subject of the selected Type II records in worksheet 2Q2026-EXCEL; DMF 39291 retains its original trailing space.
U.S. Food and Drug Administration
Explains DMF use and review. A listing or active status does not establish approval of a supplier or product.
“Are neither approved nor disapproved.”
U.S. Food and Drug Administration
FDA statement about DMFs; their technical contents are reviewed with applications that reference them.
U.S. Food and Drug Administration
Type II is broader than APIs, so the reported subject must also be checked.
“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”
U.S. Food and Drug Administration
FDA Type II category heading.
Center for Drug Evaluation, National Medical Products Administration
The October 5, 2026 export supplies the name-selected registration, with its original Chinese company name, review code, packaging, dates and blank fields.
“阿布昔替尼”
Center for Drug Evaluation, National Medical Products Administration
Exact substance name of the selected registrations in the supplied eleven-column CSV.
Liaoning Medical Products Administration
Official explanation of A and I, including joint review, qualifying prior approvals and independent API review.
“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”
Liaoning Medical Products Administration
Regulator explanation published February 18, 2025: I covers technical review not passed or a registration not yet linked to a formulation.
Compare Abrocitinib registry names, review codes and chemical identity using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
Report an Abrocitinib data issue with the page address, registry number and supporting official evidence. APIRFQ support handles data corrections. Contact the relevant company separately about material specifications, dossier access or supply.
Contact data support